HELSINKI, Finland — An artificial intelligence (AI)–based clinical decision support system helped doctors make decisions in the treatment of acute ischemic stroke and was associated with a significant reduction in recurrent vascular events in a new, randomized trial.

The AI system integrated clinician input with data from the hospital records and imaging of more than 20,000 patients in China to help guide patient management around stroke etiology and secondary prevention.

The trial represents a strong case for the future role of AI in stroke care, said Study Chair, Li Zhang, MD, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. “By harnessing AI to deliver rapid, evidence-based guidance, we’ve shown that decision support can move beyond theory into practice — improving both how we treat acute strokes and the lives of our patients.” 

However, experts not involved in the study noted that the research is based on Chinese stroke guidelines — which differ from guidelines in the United States and United Kingdom — and would need to be replicated in the West before use.

Zhang presented the results of the GOLDEN BRIDGE II trial on May 22 at the European Stroke Organization Conference (ESOC) 2025.

Keep Reading

No posts found